SRT Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions. The company serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Sartorius (ETR: SRT)
›
Sartorius (ETR: SRT) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 14,273 employees.
The shares were at 234.00 EUR on 20 November 2026, up 30.4% over 52 weeks. Its 52-week range is 158.20 EUR to 240.50 EUR: the price is 2.7% below the high and 47.9% above the low.
At a market capitalisation of 16.26B EUR, it trades at 74.5 times trailing earnings and 35.8 times forward earnings. The median trailing P/E of its 17 largest Medical Instruments & Supplies peers is 47.0, a premium of 59% for SRT. It pays a dividend yielding 0.32% (it pays out 23% of its earnings), against a median of 1.05% among the dividend payers in that peer group.
Sartorius reports return on equity of 5.7%, an operating margin of 17.8% and revenue up 9.9% year over year.
Its debt exceeds its cash by 3.68B EUR, a debt-to-equity ratio of 1.58. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 8 analysts cover the stock; their mean price target of 266.47 EUR is 13.9% above the current price. The next earnings report is expected on 23 February 2027.